A Phase 3 interventional study of Cannabidiol oral solution in Early Psychosis, sponsored by University of California, San Diego. Recruiting at 2 sites in United States. Open to participants aged 16 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-01-08.
Sponsored by University of California, San Diego · Phase 3, Interventional, and Treatment
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing cannabidiol in Psychotic Disorders — 4 open to participants now, 5 under way, 4 of them phase 3. Cannabidiol · Psychotic Disorders.
Among the 11 studies testing cannabidiol in Psychotic Disorders, this one is the 4th largest by planned enrollment, is the only one that started in 2022, is one of 4 in phase 3, and was the 8th registered.
1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.
Browse Psychotic Disorders studies →4 of the 11 studies testing cannabidiol in Psychotic Disorders are open now, in 12 countries. Recruiting first, the newest first:
University of Oxford · Sites in Austria, Germany, Greece and 6 more countries
Ages 16–40
University of Oxford · Sites in Germany, Greece, Israel and 5 more countries
Ages 16–50
University of Oxford · Sites in Austria, Canada, Finland and 7 more countries
Ages 12–35 · Healthy volunteers
By country, each count listing its studies:
Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.
This study: 16 Years to 30 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2022.
This study's planned enrollment of 120 is above the median of 65 across 1,326 interventional studies indexed under Psychotic Disorders.
Median enrollment 64 across the 11 interventional studies. Of the 5 that completed or were terminated, 4 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 11 has an industry lead sponsor. The 6 most frequent:
University of California, San Diego is the lead sponsor of 980 studies on the registry; 194 are open to participants now.
Of its 113 completed or terminated interventional studies of FDA-regulated products, 71 (63%) have results posted.
20 studies in Psychotic Disorders by University of California, San Diego: 6 open now, 7 under way, 1 of them phase 3. Of 12 finished, 8 (67%) have results posted.
Among the 20 studies in Psychotic Disorders by University of California, San Diego, this one is the 6th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2022, is the only one in phase 3, and was the 10th registered.
University of California, San Diego’s Psychotic Disorders studies by the year they started, since 2003.
1 of the studies testing cannabidiol in Psychotic Disorders that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04411225Phase 3University of California, San DiegoEffects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing cannabidiol in Psychotic Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among University of California, San Diego’s 20 in Psychotic Disorders:
This tab as a report to print or save as PDF → With an account.
This is an outpatient, single center, between-group, double blind, placebo controlled design. Approximately 120 adolescents and adult patients will be randomized to either have their treatment augmented with Cannabidiol Oral Solution (CBD) or with a matching CBD placebo for 8 weeks. The study will examine CBD as an augmentation strategy in early psychosis. It is hypothesized that CBD will improve symptoms, neurocognition, markers of inflammation and eating behaviors. Importantly, moderators and mediators of the CBD effects will be explored.
Participants will be randomly assigned in a 1:1 ratio to receive CBD or matching Placebo as an add-on to antipsychotic medication in an 8 week double blind trial. In this study, Cannabidiol Oral Solution (CBD) product will be used. This product is manufactured and supplied by GW Pharmaceuticals. The formulation is a 100 mg/mL solution. The CBD compound will be dosed at 1000mg/day administered in two divided doses. The dose of CBD was selected based on previous controlled trials that demonstrate the efficacy of CBD in patients with schizophrenia.
The maximum duration of the study from screening to follow up of outcomes and adverse events will be approximately 8 weeks. Participants will receive either the CBD or placebo within this eight.weeks and will also complete pre-treatment, midpoint (week 4) and post-treatment testing (week 8).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The cannabidiol will be administered as an oral solution to be mixed in any fluid. The formulation is 100 mg/ml. It will be administered at 500 mg at bedtime X 1 week then 500 mg BID.
Drug: Cannabidiol oral solution
Placebo will appear identical to the cannabidiol solution
Drug: Cannabidiol oral solution
Both the active drug (cannabidiol) and placebo will be in oral solution.
Also known as: Placebo
Positive and Negative Symptoms of Psychosis
Psychotic symptoms will be assessed with The Positive and negative psychotic syndrome scale (PANSS). This scale provides a summary score of all positive symptoms and all negative symptoms in participants who are already diagnosed with a psychotic disorder. The total score ranges from 30 to 210 with a higher score representing more symptoms.
Time frame: Week 7
Neurocognition
A Global Cognition Score will be assessed with Measurement and Treatment Research in Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) in all subjects.The Global Cognitive Score is a composite of the Z scores across the different cognitive domains in the MCCB. The range of scores is -1 to +1. Positive scores represent better cognitive functioning.
Time frame: week 7
Prodromal Symptoms
The Scale of Prodromal Symptoms (SOPS) is part of the Structured Interview for Prodromal Syndromes (SIPS) diagnostic interview. This scale will be used to assess subsyndromal psychotic symptoms in participants who are diagnosed as Clinical High Risk for Psychosis. Positive and Negative Symptoms will be assessed as summary scores of all positive or negative items The minimum score on the SOPS total is 0 and Maximum is 24. A higher score represents more symptoms.
Time frame: Week 7
General Symptoms
The Brief Psychiatric Rating Scale (BPRS) will be used as an assessment of overall symptom ratings with a total score in all subjects. The minimum score is 24 and maximum is 168. A higher score represents more symptoms.
Time frame: week 7
Clinical Global Impression Scale (CGI-S)
The CGI-S will provide a global psychopathology score for all subjects. The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. A "1" is considered normal while a "7" is extremely ill.
Time frame: Week 7
Peripheral Biomarkers of Inflammation
Panel of chemokines and cytokines expressed as "Mean Concentration Value". The minimum and maximum value for each measure between 0 and 40,280. In general higher values represent greater immune activation. Cytokines: Interferon-gamma, Interleukin-1, Interleukin-6, Interleukin-10, Interleukin-12p70, Tumor Necrosis Factor- alpha, Chemokines: Eotaxin-1, Eotaxin-3, Fracktalkine, Interleukin-8, Interferon Gamma-Induced Protein-10, Monocyte Chemotactic Protein-1, Macrophage-Derived Chemokine, Macrophage Inflammatory Protein-1a, Macrophage Inflammatory Protein-1b, Thymus and Activation Regulated Chemokine, Other: Brain Derived Neurotropic Factor
Time frame: week 7
Cortisol
AM Salivary Cortisol is normally in the range of 100-750 ng/dL. Higher levels are thought to represent a greater stress response.
Time frame: 7 weeks
Eating Behavior
Three Factor Eating Questionnaire will be used to query about eating behavior in different categories using total score: cognitive dietary restraint, disinhibition, and susceptibility to hunger. Each score is converted to a scaled score from 0 to 100 with the higher score representing more restraint, more dishinibition and less hunger.
Time frame: 7 weeks
Body Mass Index
Height and weight will be used to calculate Body Mass Index, a ratio of height and weight. Normal BMI is considered 18.5 to 25.
Time frame: 7 weeks
Cholesterol
serum will be drawn to measure total cholesterol, low density and high density lipoproteins along with Triglycerides. All are measured in mg/dL. Normal values include Total Cholesterol \<=199, Triglycerides 30 - 149, High Density Lipoprotein 40-59, Low Density Lipoprotein \<=129.
Time frame: Baseline and week 7
Electrophysiology Mismatch Negativity
Mismatch Negativity (MMN) measured in an event related potential paradigm. The value is expressed in micorvolts and represents the difference in response to standard versus mismatch stimuli measure at 100 milliseconds post stimuli. The mismatch negativity value varies between 0 and -6 microvolts with greater negative numbers representing greater mismatch negativity. The MMN is thought primarily to reflect the activity of sensory memory, with, at most, moderate influences of higher-level cognitive processes, such as attention.
Time frame: Baseline and week 7
Electrophysiology - Prepulse Inhibition
Prepulse Inhibition of the human startle response. Prepulse Inhibition is expressed as a percentage from 0 to 100 with the higher value presenting greater inhibition.
Time frame: Baseline and week 7
Plan to share: No
Started Jun 2022 (actual). Primary completion is estimated for Dec 2026, 54 months after the start.
Of 26 phase 3 interventional studies under Psychotic Disorders, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 72. This study's planned 54 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol
University of California, San Diego →